[JAK inhibitor].

Kunihiro Yamaoka, Yoshiya Tanaka

Research output: Contribution to journalReview article

Abstract

Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment effect as biologics. Moreover, inhibitory effect on bone destruction has been demonstrated and has been approved in 2012 as a new disease modifying anti-rheumatic drug in USA. However, since the inhibition of JAK results in inhibition of multiple cytokine signaling pathways, the clinical studies have also shown adverse events differing from biologics.

Original languageEnglish
Pages (from-to)1243-1247
Number of pages5
JournalUnknown Journal
Volume71
Issue number7
Publication statusPublished - 2013 Jul

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of '[JAK inhibitor].'. Together they form a unique fingerprint.

  • Cite this

    Yamaoka, K., & Tanaka, Y. (2013). [JAK inhibitor]. Unknown Journal, 71(7), 1243-1247.